Nordic Nanovector ASA: Mandatory notification of trade - primary insider

Oslo, Norway, 24 October 2019

Tone Kvåle, CFO, has today, 24 October 2019, purchased 5,000 shares in Nordic Nanovector ASA (the "Company") at an average share price of NOK 19.96 per share. Following this transaction, Tone Kvåle holds 45,000 PSUs, 315,000 options and 191,275 shares in the Company including shares to related party.

This information is subject to duty of disclosure pursuant to Section 4-2 and Section 5-2 of the Norwegian Securities Trading Act.

 

 

Tags:

About Us

About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Subscribe